Randomised double-blind controlled trial of Perhexiline in heart failure with preserved ejection fraction syndrome (HFpEF)

ISRCTN ISRCTN25678870
DOI https://doi.org/10.1186/ISRCTN25678870
Secondary identifying numbers 7196
Submission date
12/05/2010
Registration date
12/05/2010
Last edited
02/10/2017
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Mr Roger Beadle
Scientific

Department of Cardiovascular Medicine
Medical School
University of Birmingham
Edgbaston
Birmingham
B15 2TT
United Kingdom

Study information

Study designMulticentre randomised interventional treatment trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Other
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleRandomised double-blind controlled trial of Perhexiline in heart failure with preserved ejection fraction syndrome (HFpEF)
Study acronymPerhexiline in HFpEF
Study objectivesThis study is investigating the effect of perhexiline on patients with heart failure and preserved ejection fraction (HFpEF). Heart failure is a condtion that is defined by the heart's impaired energetic status. the trialists hypothesise that by improving the heart's energetic staus with the metabolic modulating drug perhexiline, we will improve the patients exercise capacity. This improvement in exercise capacity will be due to improved cardiac energetics and improved diastolic function.
Ethics approval(s)MREC approved (ref: 08/H1207/84)
Health condition(s) or problem(s) studiedTopic: Cardiovascular; Subtopic: Cardiovascular (all Subtopics); Disease: Cardiovascular
InterventionPerhexiline/placebo randomised in a 50:50 fashion. The perhexiline is started at 100 mg per oral twice daily (bd) and titrated according to serum levels. The medication is ceased after 3 months of therapy.

Follow-up length: 3 months
Study entry: single randomisation only
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase III
Drug / device / biological / vaccine name(s)Perhexiline
Primary outcome measurePeak oxygen consumption (VO2 max)
Secondary outcome measuresSymptomatic status (Modified Minnesota Living with Heart Failure Questionnaire)
Overall study start date01/03/2009
Completion date30/09/2012

Eligibility

Participant type(s)Patient
Age groupNot Specified
SexNot Specified
Target number of participantsPlanned sample size: 50
Key inclusion criteriaHeart failure normal ejection fraction diagnosed by signs or symptoms of heart failure and limitation on metabolic exercise testing
Key exclusion criteria1. Renal or liver impairment
2. Atrial fibrillation
3. Contraindication to magnetic resonance imaging (MRI)
4. Contraindication to perhexiline
Date of first enrolment01/03/2009
Date of final enrolment30/09/2012

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

University of Birmingham
Birmingham
B15 2TT
United Kingdom

Sponsor information

University Hospital Birmingham NHS Foundation Trust (UK)
Hospital/treatment centre

Department of Cardiothoracic Surgery
Edgbaston
Birmingham
B15 2PR
England
United Kingdom

Website http://www.uhb.nhs.uk/
ROR logo "ROR" https://ror.org/014ja3n03

Funders

Funder type

Charity

British Heart Foundation (BHF) (UK)
Private sector organisation / Trusts, charities, foundations (both public and private)
Alternative name(s)
the_bhf, The British Heart Foundation, BHF
Location
United Kingdom

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Editorial Notes

02/10/2017: No publications found, verifying study status with principal investigator.